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5-HT1B receptors (5-HT1BRs) modulate behavioral effects of cocaine. Here we examined
the effects of the 5-HT1BR agonist 5-propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-
pyrrolo[3,2-b]pyridine (CP94253) on spontaneous and cocaine-induced locomotion and
on cocaine-primed reinstatement of conditioned place preference (CPP) in male mice
given daily repeated injections of either saline or cocaine (15 mg/kg, IP) for 20 days.
In the locomotor activity experiment, testing occurred both 1 and 20 days after the
final injection. In the CPP experiment, mice underwent conditioning procedures while
receiving the last of their daily injections, which were given either during or ≥2 h
after CPP procedures. The CPP procedural timeline consisted of baseline preference
testing (days 12–13 of the chronic regimen), conditioning (days 14–19, 2 daily 30-min
sessions separated by 5 h), CPP test (day 21), extinction (days 22–34; no injections),
CPP extinction test (day 35), and reinstatement test (day 36). Mice that had not
extinguished received additional extinction sessions prior to reinstatement testing on day
42. On test days, mice were pretreated with either saline or CP94253 (10 mg/kg, IP).
Testing began 30 min later, immediately after mice were primed with either saline
or cocaine (5 mg/kg for locomotion; 15 mg/kg for reinstatement). We found that
CP94253 increased spontaneous locomotion in mice receiving repeated injections
of either saline or cocaine when tested 1 day after the last injection, but had no
effect on spontaneous locomotion after 20 days abstinence from repeated injections.
Surprisingly, cocaine-induced locomotion was sensitized regardless of whether the
mice had received repeated saline or cocaine. CP94253 attenuated expression of the
sensitized locomotion after 20 days abstinence. A control experiment in noninjected,
drug-naïve mice showed that CP94253 had no effect on spontaneous or cocaine-
induced locomotion. Mice reinstated cocaine-CPP when given a cocaine prime, and
CP94253 pretreatment attenuated cocaine reinstatement. The findings suggest that
stress from repeated saline injections and/or co-housing with cocaine-injected mice
may cross-sensitize with cocaine effects on locomotion and that CP94253 attenuates
these effects, as well as reinstatement of cocaine-CPP. This study supports the idea
that 5-HT1BR agonists may be useful anti-cocaine medications.
Keywords: serotonin, CP94253, sensitization, withdrawal, addiction, place conditioning
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INTRODUCTION
Serotonin plays a role in the reinforcing and incentive
motivational effects of cocaine and cocaine-associated cues
(Markou et al., 1993; Shaham et al., 2003). One mechanism
involved in these effects is the action of serotonin at
5-HT1B receptors (5-HT1BRs; Clark and Neumaier, 2001;
Filip et al., 2010; Miszkiel et al., 2011; Neisewander et al.,
2014). Parsons et al. (1998) discovered that 5-HT1BR agonists
shift the cocaine self-administration (SA) dose-effect function
to the left and increase responding on a PR schedule of
cocaine reinforcement, suggesting enhanced reinforcing value
of cocaine. These 5-HT1BR agonist effects are reversed by a
5-HT1BR antagonist, demonstrating that they are 5-HT1BR-
mediated. Furthermore, the agonists do not alter sucrose or
food reinforcement or locomotion at doses that enhance the
reinforcing value of cocaine (Parsons et al., 1998; Przegalin´ski
et al., 2007; Pentkowski et al., 2009). Surprisingly, we found
that both cue and cocaine-primed reinstatement of cocaine-
seeking behaviors are attenuated by 5-HT1BR agonists (Acosta
et al., 2005; Pentkowski et al., 2009). These seemingly
paradoxical findings led us to discover that 5-HT1BRs modulate
cocaine-related behaviors in opposite directions depending
on whether or not animals have undergone an abstinence
period prior to testing (Pentkowski et al., 2014). Specifically,
either the agonist 5-propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-
1H-pyrrolo[3,2-b]pyridine (CP94253) or viral overexpression of
5-HT1BRs tested during the maintenance of daily SA sessions
increased the reinforcing value of cocaine, measured as a leftward
shift of the cocaine SA dose-effect function on low ratio schedules
of reinforcement and an increase in intake on a progressive
ratio schedule (Pentkowski et al., 2012, 2014). In contrast,
after a 21-day period of protracted abstinence, the agonist
attenuated cocaine intake at the same low dose of cocaine
(0.075 mg/kg, IV) for which CP94253 had enhanced intake
prior to an abstinence period (Pentkowski et al., 2014) and
attenuated intake on a progressive ratio schedule of cocaine
reinforcement. These findings demonstrate opposite functional
effects of 5-HT1BR agonists pre- vs. post-abstinence from
cocaine SA.
5-HT1BRs also modulate spontaneous locomotion and
cocaine-induced locomotion under some circumstances. Several
studies have found that 5-HT1BR agonists stimulate locomotor
activity in drug-naïve rats (Oberlander et al., 1986, 1987;
Macor et al., 1990; Koe et al., 1992; Geyer, 1996; Chaouloff
et al., 1999), but have no effect on spontaneous locomotion
in rats with a history of cocaine SA (Przegalin´ski et al.,
2007; Pentkowski et al., 2009). 5-HT1BR agonist effects on
spontaneous locomotion may be specific to rats since the drugs
have no effect in drug-naïve mice (Bannai et al., 2007; Fish
et al., 2008; Nasehi et al., 2017). However, in mice that had
been stressed by repeated behavior testing, CP94253 increases
locomotion (Tatarczyn´ska et al., 2004, 2005). Additionally,
the 5-HT1A/1BR agonist RU24969 dose-dependently increases
spontaneous locomotion in wild type mice, but not 5-HT1BR
knockout mice (Saudou et al., 1994). CP94253, as well as another
5-HT1BR agonist CP93129, have been shown to potentiate
cocaine-induced locomotion and cocaine sensitization in rats
(Przegalin´ski et al., 2001, 2002, 2004; Filip et al., 2010).
Collectively, these findings suggest that 5-HT1BR stimulation
enhances locomotion in rodents given cocaine or with a history
of stress.
One goal of the present study was to examine whether the
abstinence-induced ‘‘switch’’ in 5-HT1BR functional modulation
of cocaine-related behaviors observed in rats previously is
also observed in mice. To this end, we investigated whether
CP94253 produces opposing effects on spontaneous and cocaine-
induced locomotion before and after an abstinence period in
C57BL/6 male mice receiving daily injections of either saline
or cocaine (15 mg/kg, IP) for 20 days. The second goal was
to investigate whether the incentive motivational effects of a
cocaine priming injection are attenuated by 5-HT1BR agonist
treatment in mice that had undergone abstinence, similar to
the decrease in cocaine-primed reinstatement of cocaine-seeking
behavior observed previously in rats (Pentkowski et al., 2012,
2014). To this end, we investigated CP94253 effects on cocaine-
primed reinstatement of extinguished cocaine-conditioned place
preference (CPP).
MATERIALS AND METHODS
Animals
Male C57BL/6 mice arrived at 5 weeks old from Jackson
Laboratories (Sacramento, CA, USA) and were group housed
3–4/cage in a climate-controlled facility with a reversed
10 h light/14 h dark cycle (lights off at 6:00 AM). Mice
were handled for 2 weeks. For the CPP experiment only,
mice were transferred to single housing 1 day prior to the
start of behavior testing. Food and water were provided
ad libitum in the home cage. All behavioral testing occurred
between 8 AM and 4 PM. Separate groups of experimentally
naïve mice were used for each specific experiment. All
husbandry and procedures adhered to the National Research
Council (US) Committee for the Update of the Guide for
the Care and Use of Laboratory Animals (2011), and all
experimental procedures were reviewed and approved by the
Institutional Animal Care and Use Committee at Arizona State
University.
Drugs
Cocaine hydrochloride (RTI International, Research Triangle
Park, NC, USA) and CP94253 (Tocris Bioscience, Minneapolis,
MN, USA) were dissolved in bacteriostatic saline. All drugs were
injected at a volume of 10 ml/1 kg of body weight. The doses
used had been previously reported to produce cocaine- (Tilley
et al., 2007; Shuman et al., 2012; Rao et al., 2013) and CP94253-
induced hyperlocomotion in mice injected 30 min before testing
(Tatarczyn´ska et al., 2004, 2005; Bannai et al., 2007; Fish et al.,
2008).
Apparatus
Locomotor activity tests were conducted in Plexiglas chambers,
each measuring 35 × 24 × 31 cm high. The chambers
had corn cob bedding on an acrylic floor and alternating
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black and white stripes on the walls. CPP experiments were
conducted in Plexiglas two-compartment apparatus with each
end compartment measuring 35 × 24 × 31 cm high and
with a removable partition separating them. One compartment
had cedar bedding beneath a wire 1 × 1 cm grid floor
and alternating black and white vertical stripes on the walls.
The other compartment had pine bedding beneath a parallel
bar floor (5 mm diameter) and alternating black and white
horizontal stripes on the walls. In order to prevent the mice
from escaping from the chambers, while maintaining the ability
to record their behavior via an overhanging video camera,
a rectangular tower measuring 70 × 24 × 74 cm high of
clear Plexiglas was used as an extension of the apparatus. The
testing room was dimly lit with two overhead lamps, each
containing a 25 Watt light bulb. A camera (Panasonic WV-
CP284, color CCTV, Suzhou, China) used to record testing
sessions was mounted 101 cm above the center of each
apparatus. A WinTV 350 personal video recorder (Hauppage,
NJ, USA) captured live video encoded into MPEG streams. A
modified version of TopScan Software (Clever Sys Incorporated,
Reston, VA, USA) was used to track the animals’ movement.
This program uses the orientation of an animal’s body parts
(e.g., nose, head, center of body, forepaws, base of tail,
etc.) to identify the animal’s location and specified behaviors.
Experiment 1: Effects of CP94253 on
Spontaneous and Cocaine-Induced
Locomotion before and after Chronic Daily
Injections of Cocaine or Saline
The timeline for Experiment 1 is shown in Figure 1A. Adult,
male C57BL/6 mice (n = 91) were housed four/cage, with
two mice in each cage assigned to receive saline and two assigned
to receive cocaine (15 mg/kg, IP) at the same time of day
for 20 consecutive days. The mice were further assigned to
receive two different pretreatments on the test days. The first
pretreatment was either vehicle or CP94253 (10 mg/kg, IP)
and the second pretreatment was either a saline or cocaine
(5 mg/kg, IP) challenge injection. Thus the design of this
experiment was a 2 (chronic saline or cocaine) × 2 (vehicle
or CP94253 pretreatment) × 2 (saline or cocaine challenge)
factorial with eight treatment groups (n = 8–11/group). Test day
1 took place on the day after the last chronic injection. After
test 1, the mice underwent a 20-day period of no injections
during which they remained in the colony room and their tails
were marked twice per week to maintain identification. Test
day 2 took place the day after the final abstinence (i.e., no
injection) day. On both of the test days, mice were first
placed into the test chamber for 1 h to allow for habituation.
Immediately following this baseline period, mice were injected
with either vehicle or CP94253 and were returned to their
home cage for 30 min. Next, mice received the saline or
cocaine challenge injection and were returned to the test
chamber for an additional 60 min. We used a lower cocaine
dose for the challenge (5 mg/kg) on test day than that used
during the daily repeated administration (15 mg/kg). This was
done in order to avoid potential ceiling effects for detecting
FIGURE 1 | Timeline for Experiments 1–2 (A) and distance traveled
(meters ± SEM) by mice that received either chronic daily injections of saline
(B) or 10 mg/kg cocaine (C) and were tested both 24 h after the last of
20 injections (i.e., before abstinence, white bars) and 20 days after (i.e., after
abstinence, gray bars), n = 8–11/group. Contrary to prediction, there was no
effect of chronic treatment conditions nor interactions with cocaine challenge
(0 or 5 mg/kg, IP) or 5-propoxy-3-(1,2,3,6-tetrahydro-
4-pyridinyl)-1H-pyrrolo[3,2-b]pyridine (CP94253) (0 or 10 mg/kg, IP), so further
analyses were conducted averaged across the chronic treatment variable (D).
This analysis yielded a challenge injection by day interaction (E) and a
pretreatment by day interaction (F). Asterisk (∗) represents a significant
post hoc comparison, p < 0.05; Plus sign (+) represents a significant planned
comparison, p < 0.05. Double plus (‡) represents a significant difference from
respective vehicle condition, Bonferroni t-test p < 0.001.
sensitization of locomotion, a well-known effect of repeated
cocaine administration (Ago et al., 2008; DiRocco et al., 2009;
Luo et al., 2010; Thompson et al., 2010; Riday et al., 2012; Robison
et al., 2013).
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Experiment 2: Effects of CP94253 on
Spontaneous and Cocaine-Induced
Locomotion in Mice without the Repeated
Injection Regimen
In order to assess potential injection stress effects, we repeated
Experiment 1 using identical procedures and timeline except
that the 5 week old, male C57BL/6 mice (n = 47) did
not receive any injections during the first 20 days of the
experiment. Thus, the four mice/cage were simply handled
twice a week to color-mark tails for identification purposes
and were otherwise left undisturbed to minimize stress. The
design was a 2 (vehicle or CP94253 pretreatment) × 2 (saline
or cocaine challenge) factorial with four treatment groups
(n = 11–12/group). Test day procedures were identical to
Experiment 1.
Experiment 3: Effects of CP94253 on
Reinstatement of Extinguished
Cocaine-CPP
The timeline for Experiment 3 is shown in Figure 3A.
Adult, male C57BL/6 mice received daily injections of cocaine
(15 mg/kg, IP) or saline for 11 days in order to keep the
same number of cocaine injections prior to testing for effects
of CP94253 in this experiment as that given in the previous
experiments. Additionally, the mice were housed three/cage and
all three mice/cage were assigned to the same chronic drug
condition. On day 12 and 13 the mice were allowed free access
to both sides of the CPP apparatus for 15 min to habituate them
to the novel environments and to assess initial compartment
preference. The average of the time spent in the least preferred
compartment on days 12 and 13 was used as the baseline
preference measure. On both days 12 and 13, mice received
their chronic daily injection (saline or cocaine) in their home
cage 2–3 h after the preference test. On days 14–19, the mice
underwent two daily 30-min conditioning sessions separated by
a 5-h period. During the morning session, mice were injected
with saline and were placed into their initially preferred side and
during the afternoon session mice were injected with cocaine
(15 mg/kg, IP) or saline and were placed into their initially
non-preferred side. On day 20, mice were not exposed to the
apparatus, but did receive either saline or cocaine (15 mg/kg,
IP) at the same time of day as all previous injections. On
day 21, mice were tested for the expression of cocaine CPP
for 15 min. Only 80% of the mice met the CPP expression
criterion (spent >450 s in initially non-preferred compartment)
and continued in the experiment. These mice next underwent
extinction training on Days 22–34. During extinction, the mice
received one 30-min exposure to one of the compartments each
day, with the particular compartment alternating across the days.
On day 35, mice were tested for 15 min to demonstrate that their
CPP had extinguished. Mice that extinguished were tested for
reinstatement of CPP the following day (day 36). On test day,
mice received either saline or CP94253 (10 mg/kg, IP) 30 min
prior to the test. Immediately before the test, the mice were
primed with either saline or cocaine (15 mg/kg, IP). Mice that
did not initially extinguish received four more days of extinction
with two, 30-min sessions per day, one in each compartment.
They again received a 15-min preference test to demonstrate
that their CPP had extinguished. Mice that extinguished were
tested for reinstatement of CPP the following day. Mice that
failed to extinguish were removed from the study. The design
of the study was a 2 (vehicle or CP94253 pretreatment) × 2
(saline or cocaine challenge) factorial with four treatment groups
(n = 9–11/group). Additionally, a group of mice (n = 14) were
treated chronically with saline, conditioned with saline during
both daily sessions, extinction-trained, and given a saline prime
prior to testing (i.e., saline control group).
Statistics
Drug-induced changes in distance traveled (meters) were
analyzed and graphed for the first 30 min of each testing
session. Only the first 30 min of the testing sessions were
analyzed because cocaine is rapidly metabolized in mice (Tilley
et al., 2007; Rao et al., 2013) and the difference from baseline
calculation controlled for individual differences in baseline
activity. The changes in distance traveled measures were analyzed
by mixed factor analysis of variances (ANOVAs) with the
following between group variables: chronic treatment with
cocaine or saline (Experiment 1 only); pretreatment with
CP92453 or vehicle; challenge with cocaine or saline prior
to test. The ANOVAs also included Test day as a within
subjects repeated measure. Interactions were further analyzed
by smaller ANOVAs and t-test with Bonferroni correction
for multiple comparisons where appropriate. In addition,
planned comparisons were conducted to test our hypothesis
that CP94253 would enhance spontaneous locomotion and
cocaine-induced locomotion pre-abstinence, but would have the
opposite effect post-abstinence. Mice whose distance traveled
score was more than ±2 standard deviation from the mean
were deemed outliers and removed from all analysis. For CPP,
time spent in the initially non-preferred side was analyzed by
ANOVA with test days as a repeated measure. The test days
included the baseline preference test, the CPP test (occurred
after six daily pairings with cocaine), and the extinction test
(occurred after 18–22 sessions of extinction). This analysis was
a manipulation check to demonstrate that cocaine-conditioned
rats exhibited CPP and extinction of CPP. To analyze cocaine-
primed reinstatement of CPP, time spent in the initially
non-preferred compartment of the apparatus (drug-paired
compartment) was analyzed by a 2 (Pretreatment: CP94253 and
vehicle) × 2 (Priming injection: Cocaine and saline) AVOVA.
Interactions were analyzed by smaller ANOVAs and Tukey post
hoc tests.
RESULTS
Experiment 1: Effects of CP94253 on
Spontaneous and Cocaine-Induced
Locomotion before and after Chronic Daily
Injections of Cocaine or Saline
We first tested the hypothesis that mice given chronic
cocaine treatment would exhibit a ‘‘switch’’ in 5-HT1BR
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FIGURE 2 | Distance traveled (meters ± SEM) by injection-naïve mice that were treated the same as mice in the previous experiment (see timeline on Figure 1)
except that they were not given daily injections over the first 20 days of the experiment, but were instead left undisturbed in their home cages except for twice weekly
tail marking for identification. On the test days, the mice received an injection of either saline or CP94253 (10 mg/kg, IP) and 30 min later received a saline or cocaine
(5 mg/kg, IP) injection (n = 11–12/group). Plus sign (+) represents a significant difference from saline-challenged groups, p < 0.001.
agonist effects from facilitation of cocaine-induced locomotion
during the treatment phase to inhibition of cocaine-induced
locomotion after a period of abstinence from chronic cocaine.
Surprisingly, the chronic saline group behaved similarly to
the chronic cocaine group (Figures 1B,C) and the analysis
confirmed that there was no main effect nor interactions
with chronic treatment (i.e., chronic saline vs. cocaine).
Therefore, subsequent analyses were conducted with the
data are averaged across chronic condition as shown in
Figure 1D. This analysis revealed a main effect of Challenge,
where the cocaine challenge increased locomotion compared
to the saline challenge when averaged across pretreatment
with Vehicle or CP94253 (F(1,87) = 62.28, p < 0.001).
However, there was also a Challenge by Day interaction
(F(1,87) = 15.47, p < 0.001) as shown in Figure 1E.
Subsequent pairwise comparisons with Bonferroni correction
indicated that cocaine-challenged mice showed no difference
in locomotion across test days, whereas saline challenged mice
showed a decrease in locomotion after abstinence compared
to before abstinence (t(43) = 5.8, p < 0.001). There was
also a Pretreatment by Day interaction (F(1,87) = 32.83,
p < 0.001) as shown in Figure 1F. Subsequent pairwise
comparisons indicated that mice pretreated with vehicle
showed no difference in locomotion across test days, whereas
mice pretreated with CP94253 showed less locomotion after
abstinence compared to before abstinence (Bonferroni t-test,
t(44) = 5.8, p < 0.001). In addition to the ANOVAs,
planned comparisons were conducted to test the hypothesis
that CP94253 pretreatment would facilitate spontaneous and
cocaine-induced locomotion before abstinence but inhibit these
behaviors after abstinence. The results of these comparisons
indicated that there was a significant increase in spontaneous
locomotion after the CP94253 pretreatment compared to vehicle
pretreatment in mice challenged with saline before abstinence
from repeated injections (t(42) = 3.0, p < 0.01, Figure 1D).
In mice challenged with cocaine, there was no difference in
cocaine-induced locomotion between vehicle- and CP94253-
pretreated mice before abstinence, but the CP94253-pretreated
mice showed less cocaine-induced locomotion than vehicle-
pretreated mice after abstinence (t(45) = 3.6, p < 0.05,
Figure 1D).
Experiment 2: CP94253 Has no Effect in
Mice that Have Not Undergone a Repeated
Injection Regimen
The finding that chronic cocaine vs. chronic saline treatment did
not show differences in locomotion in the previous experiment
was puzzling. We reasoned that stress experienced by the saline
control group may have cross-sensitized the mice to cocaine
such that both groups (i.e., chronic cocaine and chronic saline)
showed sensitized responses to cocaine (Sorg, 1992). Indeed, the
control mice experienced repeated injections and were housed
with cocaine-treated mice, and both of these manipulations are
chronic stressors in mice (Ryabinin et al., 1999; Hoplight et al.,
2007). Another concern was that rather than CP94253 having
opposite effects on cocaine-induced locomotion before and after
abstinence from repeated injections, perhaps the agonist simply
has opposite effects the first time it is administered compared
to the second time it is administered. We examined these
possibilities in this experiment. Naïve, non-injected mice arrived
at the same age as in the previous experiment and were housed
for 20 days during which they were handled twice weekly to
color-mark tails for identification purposes and were otherwise
left undisturbed. As expected, cocaine increased locomotion to
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FIGURE 3 | Timeline for Experiment 3 (A) and results of 15-min preference tests to assess baseline preference, cocaine-conditioned place preference (CPP), and
extinction of cocaine-CPP (B). Subsequently, mice that had received repeated saline injections (white bars) or repeated cocaine injections (black bars) prior to and
during conditioning were tested for reinstatement of CPP (C) following pretreatment with either saline or CP94253 (10 mg/kg, IP) and a priming injection of either
saline (Sal) or cocaine (15 mg/kg, IP; Coc) 30 min later and immediately prior to the test (n = 9–11/group). Values are the time (s ± SEM) in the initially non-preferred
compartment (i.e., cocaine-paired side for conditioned mice) and dashed line represents 50% of the total test time such that values above the line illustrate a
preference switch. Asterisk (∗) represents difference from saline group, Bonferroni t-test p < 0.001. Plus (+) represents difference from all other groups, Tukey test,
p < 0.05.
a similar degree on the first (day 21) and second (day 42) test
days as there was a main effect of Challenge (F(1,43) = 15.15,
p < 0.001), but no interactions with Pretreatment or Day. In
contrast to the effects of CP94253 observed in the repeatedly
injected saline controls (Figure 1B), CP94253 had no effects
on locomotion in injection-naive mice (Figure 2). This finding
suggests that the saline injections in mice from the previous
experiment did indeed produce stress that affected spontaneous
and cocaine-induced locomotor activity in a 5-HT1BR-sensitive
manner.
Experiment 3: CP94253 Prevents
Cocaine-Primed Reinstatement of
Extinguished Cocaine CPP
Approximately 40% of the mice preferred the side of the
apparatus with horizontal stripes and ∼60% preferred the
side with vertical stripes, confirming the use of an unbiased
apparatus. A repeated measures analysis across the baseline,
CPP, and extinction tests showed a significant day by
conditioning treatment interaction (F(2,106) = 13.23, p < 0.001;
Figure 3B). Subsequent analyses comparing saline to cocaine
conditioned groups on each test day showed a group difference
on the CPP test day but no difference during baseline
or extinction (Bonferroni t-test t(51) = 3.98, p < 0.001).
These results indicate that cocaine conditioning produced CPP
that was abolished by extinction training. In the cocaine
conditioned groups, a 2 × 2 ANOVA of time spent in
the drug-paired side during the reinstatement test revealed
a significant Pre-treatment × Priming injection interaction
(F(1,35) = 4.26, p < 0.05; Figure 3C). Subsequent post hoc
analyses indicated that the cocaine-primed, saline-pretreated
group showed significantly greater CPP than all other groups
(Tukey tests, p < 0.05). In addition, comparisons of each
group to its extinction baseline indicated that only the
cocaine-primed group showed a significant increase in time
spent in the drug-paired side relative to extinction baseline
(t(10) = 4.1, p < 0.005). Finally, the cocaine-primed, saline-
pretreated group also showed a significantly greater amount
of time spent in the drug-paired side relative to the saline
controls (t(23) = 2.4, p < 0.05). These results suggest
that CP94253 attenuated cocaine-primed reinstatement of
cocaine CPP.
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DISCUSSION
This study yielded partial support for our hypothesis that
mice would show a similar abstinence-dependent change in
5-HT1BR modulation of cocaine effects as observed previously
in rats (Pentkowski et al., 2009, 2012, 2014). We predicted
that the 5-HT1BR agonist CP94253 would facilitate cocaine-
induced locomotion in mice given repeated daily injections
of cocaine, but would inhibit this behavior after a 20-day
period of abstinence, similar to the ‘‘switch’’ in 5-HT1BR
agonist effects observed in rats before and after abstinence
from cocaine SA. Surprisingly, we found that CP94253 effects
on locomotion were the same regardless of whether or not
the mice received repeated injections of saline or cocaine
(Figures 1B,C). We then conducted further analyses without
the chronic treatment as a factor (Figure 1D). We found that
acute administration of CP94253 initially increased spontaneous
locomotion in mice tested on the 21st day of their chronic
injections as predicted; however, the agonist did not alter
spontaneous locomotion after a 21-day abstinence phase.
Furthermore, the effects of the agonist on cocaine-induced
locomotion only partially supported our predictions because
CP94253 failed to alter this behavior initially, but did reverse
the cocaine-sensitized hyperlocomotion observed after 20 days
abstinence from daily repeated injections. Overall, the results
are generally consistent with previous findings in rats of
a facilitatory effect on cocaine-induced behavior prior to
abstinence and an inhibitory effect after a prolonged period of
abstinence.
We had expected that the chronic repeated cocaine injections
would sensitize mice to the cocaine challenge given on the
first test day and that this effect would be evident as greater
locomotor activity in the chronic cocaine-injected group relative
to the chronic saline-injected control group. Because there was
no difference between these groups, we speculated that our
chronic repeated saline injections may have stressed the mice
in the experiment resulting in stress-induced cross-sensitization.
Previous research has demonstrated cross-sensitization between
repeated stress and repeated cocaine injections in both rats
and mice (Sorg, 1992; Prasad et al., 1995; Kikusui et al., 2005;
Maeda et al., 2006; Boyson et al., 2014), and repeated injections
are stressful in both mice and rats (Ryabinin et al., 1999;
Ferguson et al., 2009). Another possible stressor was that the
control mice were cohoused with the cocaine-treated mice, which
may have resulted in chronic social stress. Although we did
not notice overt signs of stress such as aggression, Hoplight
et al. (2007) have previously shown that saline-injected rats
pair housed with cocaine-injected rats have altered 5HT1BR
profiles similar to that of cocaine treated rats, but not those
housed with saline treated rats. To test this stress cross-
sensitization hypothesis, we examined spontaneous and cocaine-
induced locomotion in mice that were group housed and left
undisturbed for 20 days except for tail-marking twice/week.
In these control mice, the second cocaine challenge failed to
sensitize locomotion in contrast to the sensitized locomotion
observed in mice that were co-housed with cocaine-injected mice
and given chronic saline injections. Furthermore, CP94253 failed
to alter either spontaneous or cocaine-induced locomotion
on either test day in the noninjected control mice. It is
important to note that these control mice were tested on
two separate occasions after receiving CP94253 pretreatment,
mitigating the idea that CP94253 may simply produce different
effects the first vs. second time it is given. The different
pattern of behavior across the chronic saline-injected and
noninjected mice, coupled with the similar pattern of behavior
in the chronic cocaine-injected and chronic saline-injected mice,
support the interpretation that stress from repeated injection
and living with cocaine-injected mice cross-sensitized the mice
to cocaine. CP94253 reversed expression of the sensitized
locomotion after a period of abstinence. Although the neural
mechanisms underlying the stress cross-sensitization effects will
require further investigation, one likely pathway contributing
to these effects is the 5-HT1BR-expressing medium spiny
neurons projecting from nucleus accumbens (NAc) shell to the
VTA. Previous research has shown that 5-HT1BR located on
GABAergic projection neurons from the NAc shell to the VTA
may mediate stress cross-sensitization with psychostimulant
drugs (Furay et al., 2011; Miczek et al., 2011; Nair et al.,
2013).
Although we had predicted that CP94253 would attenuate
cocaine-sensitized locomotion after a period of abstinence,
a previous study by Przegalin´ski et al. (2001) showed that
while CP94253 dose-dependently enhances hyperlocomotion
produced by acute amphetamine administration in mice, it does
not affect amphetamine sensitization. The present findings seem
discrepant with those of Pentkowski et al. (2009, 2012) however,
we suggest that CP94253 may differentially alter locomotion
induced by cocaine vs. amphetamines based on recent work
from our laboratory demonstrating a different pattern of
changes in cocaine vs. methamphetamine SA. Unlike the
enhancement of cocaine SA prior to abstinence, CP94253 reduces
methamphetamine SA both before and after abstinence (Garcia
et al., 2017).
As we had predicted, CP94253 attenuated the cocaine-primed
reinstatement of extinguished cocaine-CPP in mice that had a
history of chronic cocaine administration followed by protracted
abstinence prior to testing. Neither CP94253 pretreatment
alone nor a saline prime prior to reinstatement testing altered
preference. These control data suggest that reinstatement was
specific to cocaine priming and that CP94253 specifically
reversed the cocaine priming effect rather than nonspecifically
altering preference. The findings are consistent with previous
research suggesting that 5-HT1BR agonists attenuate incentive
motivational effects of cocaine priming injections in the
operant extinction/reinstatement model (Przegalin´ski et al.,
2002, 2007; Pentkowski et al., 2014). Collectively, the studies
suggest that 5-HT1BRs modulate the incentive motivational
effects of a cocaine prime in both rats and mice (Parsons
et al., 1998; Fletcher et al., 2002; Pentkowski et al., 2012,
2014).
Demonstrating effects of 5-HT1BR agonists on
psychostimulant-induced and conditioned behaviors in mice
is important because transgenic mice are a valuable tool for
investigating the neural mechanisms of these behaviors. A
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leading hypothesis for the effects of the agonists on cocaine-
induced behaviors suggests that 5-HT1BRs inhibit either
GABAergic interneurons in the VTA or GABAergic medium
spiny neurons projecting from the NAc to VTA, and this
action disinhibits DA neurons (Parsons et al., 1999; Yan
and Yan, 2001; Neumaier et al., 2002; O’Dell and Parsons,
2004; Barot et al., 2007; Hoplight et al., 2007). For instance, a
microdialysis study suggests that stimulating 5-HT1BRs in the
VTA inhibits GABA release from the neurons that tonically
inhibit mesolimbic DA neurons. This leads to disinhibition
of the mesolimbic DA neurons, increasing dopaminergic
transmission in the NAc (O’Dell and Parsons, 2004). Because
viral-mediated overexpression of 5-HT1BRs in this pathway
attenuates cocaine intake after abstinence (Pentkowski et al.,
2012), it is likely that cocaine abstinence causes adaptations
within the 5-HT1BR→GABAR→DA circuit in the VTA,
which may underlie the inhibitory effects of 5-HT1BR agonists
on cocaine-induced behaviors that are observed following
protracted abstinence. Transgenic mice may be useful in
elucidating the neural circuitry involved in 5-HT1BR agonists
effects on cocaine-induced behavior.
In conclusion, this study demonstrates that a 5-HT1BR
agonist reverses expression of cocaine sensitization and blocks
cocaine-primed reinstatement of cocaine-CPP in mice. These
findings offer further support for the idea that serotonin inhibits
incentive motivational effects of cocaine through an action at
5-HT1BRs. Furthermore, this research suggests that 5-HT1BRs
may be a useful target for developing medications for cocaine
use disorders and that mice are a useful model for screening the
potential anti-cocaine therapeutic effects of 5-HT1BR agonists,
as well as for investigating the neural mechanisms involved
in 5-HT1BR-mediated inhibition of the incentive motivational
effects of cocaine.
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